Related Experiment Video

Updated: Aug 12, 2026

Biochemical Titration of Glycogen In vitro
07:16

Biochemical Titration of Glycogen In vitro

Published on: November 24, 2013

Carbohydrate content and regulation following injection of different glycogenolytic enzymes

I Lundquist

    Enzyme
    |January 1, 1975
    PubMed

    Insights

    Acid amyloglucosidase, but not phosphorylase, reduced liver glycogen and blood glucose in mice. This enzyme also enhanced insulin release stimulated by glucose and other secretagogues, suggesting varied insulin secretion mechanisms.

    Area of Science:

    • Biochemistry
    • Endocrinology
    • Metabolic Regulation

    Background:

    • Glycogenolysis is a key process in glucose homeostasis.
    • Enzymes involved in glycogen breakdown can influence blood glucose and insulin levels.
    • Understanding these enzymatic effects is crucial for metabolic research.

    Purpose of the Study:

    • To investigate the impact of glycogenolytic enzymes on carbohydrate metabolism and insulin release in mice.
    • To differentiate the effects of phosphorylase versus hydrolytic enzymes like alpha-amylase and acid amyloglucosidase.
    • To explore the influence of acid amyloglucosidase on insulin secretion stimulated by various secretagogues.

    Main Methods:

    • Mice were injected with glycogenolytic enzymes: phosphorylase, alpha-amylase, and acid amyloglucosidase.
    • Measurements included tissue glycogen (liver and muscle), blood glucose, and plasma insulin levels.
    • Insulin release was assessed in response to different secretagogues after enzyme pretreatment.

    Main Results:

    • Phosphorylase injection had no observable effects.
    • Alpha-amylase and acid amyloglucosidase reduced liver glycogen levels.
    • Acid amyloglucosidase decreased blood glucose, slightly elevated plasma insulin, and significantly increased insulin release stimulated by tolbutamide, glibenclamide, leucine, isoleucine, lysine, and glucose.
    • Muscle glycogen remained unaffected by all enzymes at the tested doses.
    • Insulin release stimulated by IPNA, ACTH, glucagon, and CCK-PZ was not affected by amyloglucosidase.

    Conclusions:

    • Acid amyloglucosidase significantly impacts carbohydrate metabolism and insulin regulation in mice.
    • The differential effects of amyloglucosidase on insulin secretagogues suggest distinct mechanisms underlying insulin secretion.
    • These findings provide insights into the complex regulation of glucose homeostasis and insulin release.

    More Related Videos

    The Extraction of Liver Glycogen Molecules for Glycogen Structure Determination04:50

    The Extraction of Liver Glycogen Molecules for Glycogen Structure Determination

    Published on: February 8, 2022

    Radiochemical Assessment of Glycogen Synthase Enzyme Activity in Animal Tissue02:30

    Radiochemical Assessment of Glycogen Synthase Enzyme Activity in Animal Tissue

    Published on: October 24, 2025

    Related Concept Videos

    Hormones Regulating Blood Glucose01:16

    Hormones Regulating Blood Glucose

    Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
    In addition to accelerating glucose uptake and utilization, insulin has...
    Glucose Homeostasis: Regulation of Blood Glucose01:02

    Glucose Homeostasis: Regulation of Blood Glucose

    Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
    During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
    Insulin Formulations: Types and Delivery01:27

    Insulin Formulations: Types and Delivery

    Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
    Short-acting insulins are divided into rapid-acting...
    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
    Hypoglycemia and Glucagon01:15

    Hypoglycemia and Glucagon

    Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...